9999999997-18-007532.txt : 20180830 9999999997-18-007532.hdr.sgml : 20180830 20180830161339 ACCESSION NUMBER: 9999999997-18-007532 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180830 DATE AS OF CHANGE: 20180830 ACTION DATE: 20180830 RECEIVED DATE: 20180830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36395 FILM NUMBER: 181047249 BUSINESS ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-926-7655 MAIL ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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